SGLT-2 inhibitors (SGLT2i) reduce cardiovascular (CV) risk in people with type 2 diabetes and atherosclerotic CV diseases. The inflammatory function of macrophages (Mφ) - which play a pivotal role in atherosclerosis - is strictly dependent on their metabolism.

Aim: To determine whether empagliflozin (EMPA) reduces inflammation and modifies bioenergetic metabolism in proinflammatory human Mφ (M1).

Methods: M1 were differentiated from healthy donors’ monocytes and incubated with/without EMPA 100 µM for 16h. Biomarkers of inflammation and oxidative stress were quantified by qPCR. Steady-state energetic metabolism (fluxes: pmol/min for 5x104 cells) was measured by indirect microcalorimetry [oxidations of lipids (LipOX,) glucose and amino acids; anaerobic glycolysis (AnaerGlyc); tricarboxylic acid cycle (TCA); energy expenditure (EPR); maximum estimate of ATP production (ATPflux)] which is based on the integration of measured O2 and H+ (Agilent Seahorse), lactate and NH4 (enzymatic method) fluxes with the stoichiometric equations of metabolic pathways.

Results: In M1, EMPA reduces (≈50%) inflammation (IL1β, IL8, TNFα and MCP1; p<0.05-0.001) and oxidative stress (GPX and HO-1; p <0.05). EMPA lowers OCR (133±9.7 vs. 153±10.3, p<0.001), LipOX (1.15±0.1 vs. 1.33±0.1; p<0.005), TCA (45±3 vs. 52±4; p<0.001), AnaerGlyc (210±23 vs. 268±24; p<0.01), ATPflux (1097±94 vs. 1313±94; p<0.005) and EPR (83±7 vs. 98±7 µJ/min; p<0.001). After dissipating mitochondrial membrane potential and forcing maximal OCR with FCCP, TCA (77±11 vs. 97±12, p=0.001), LipOX (1.7±0.3 vs. 2.2±0.4, p<0.005) and EPR (125±17 vs. 153±17; p<0.005), but not AnaerGlyc, remain inhibited by EMPA.

Conclusions: EMPA alters M1 inflammation along with cytosolic (AnaerGlyc) and - to a greater extent - mitochondrial (TCA) bioenergetics. EMPA-induced metabolic dysfunction of M1 in vivo might result into reduced metaflammation and contribute to SGLT2i-dependent CV protection.

Disclosure

V. Spigoni: None. G. Cinquegrani: None. F. Fantuzzi: None. S. Lorusso: None. A. Dei cas: Other Relationship; Self; Novo Nordisk. R. C. Bonadonna: Advisory Panel; Self; Sanofi, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company.

Funding

Italian Diabete Ricerca Foundation; Eli Lilly Italy

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.